View Archive

1st Annual European Symposium on Lung Cancers™

1st Annual European Symposium on Lung Cancers™

7-8 July 2017
Barcelona, Spain

Crowne Plaza Barcelona – Fira Center
Av. de Rius i Taulet, 1,
08004 Barcelona, Spain
Tel: +34 934 26 22 23


Hotel Information Link

The field of lung cancer therapy now encompasses several cutting-edge approaches, including personalized medicine, targeted agents, and immunotherapy. After decades of therapeutic nihilism, the treatment of patients with lung cancer has rapidly moved to the vanguard of clinical oncology, incorporating treatments with a superior therapeutic index compared to the previous standard of cytotoxic regimens. These practice-changing discoveries have the potential to improve patient outcomes, but also place an increased demand on physicians to understand new paradigms in molecular testing, treatment selection, and managing adverse events with new categories of therapies.

We are pleased to announce the 1st Annual European Symposium on Lung Cancers™, which will focus on these “Disruptive Therapeutic Innovations in Lung Cancer” and how clinicians can best incorporate these new approaches. This highly interactive and practical program will include internationally recognized experts in lung cancer describing recent key studies in lung cancer, as well as extensive case-based discussions that go beyond the data in addressing challenges faced in the clinic. This meeting will also allow for participants to engage directly with the experts and with their peers to share their perspectives, personal experiences, and approaches to optimize care for their patients with lung cancer.

2017 Featured Topics

  • Immunotherapy as a new standard of care in the first-line setting and in previously treated patients
  • Current and future approaches for selecting patients for immunotherapy
  • Management of immune-related adverse events
  • New therapies for patients with EGFR mutation-positive and ALK-rearranged NSCLC
  • Clinical data on targeted agents for other oncogenic drivers, including BRAF, MET, and RET
  • The emergence of liquid biopsies for molecular testing, and what oncologists need to know for their optimal application

Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, as well as other healthcare professionals involved in the treatment and management of patients with lung cancer.

Learning Objectives

At the conclusion of this symposium, you should be better prepared to:

  • Assess methods by which prognostic and predictive tumor characteristics can be identified in advanced forms of lung cancer
  • Utilize tumor and patient characteristics to optimize personalized treatment sequencing for patients with advanced NSCLC
  • Discuss current and emerging roles for single agent and combination immunotherapeutic strategies in the management of advanced lung cancers
  • Apply personalized approaches to manage EGFR-mutated advanced NSCLC by assessment of mutation subtypes in multiple lines of care
  • Assess evolving data sets concerning the use of ALK inhibition in front-line and subsequent lines of care in advanced NSCLC
  • Discuss emerging targeted approaches for oncogenic drivers in NSCLC beyond EGFR and ALK
  • Identify approaches to address treatment-related toxicities in patients with lung cancer
  • Integrate personalized approaches to manage challenging cases in advanced lung cancer settings

Program Co-Chairs

Prof. Dr. med. Martin Reck
Head of the Thoracic Oncology and Clinical Trial Departments
Lung Clinic Grosshansdorf
Grosshansdorf, Germany

Jean-Charles Soria, MD, PhD
Cancer Specialist
Chair, Drug Development Department,
Gustave Roussy
Professor of Medicine and Medical Oncology at South-Paris University
Paris, France

European Planning Committee

Enriqueta Felip, MD, PhD
Director Thoracic and Head and Neck Program
Department of Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain

Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE
Honorary Chair in Pulmonary Pathology
Aberdeen University Medical School
Aberdeen, Scotland

Tony Mok, MD
Chairman, Dept. of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China

Solange Peters, MD-PhD, PD-MER
Head Medical Oncology
Chair Thoracic Malignancies
Oncology Department
Lausanne University Hospital
Lausanne, Switzerland


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19

I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.

I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.

* By checking this box, you have read and understand the above and agree to its terms.

Calendar of Events
Filter By